Findings

What do systematic reviews say?

873 questions · 883 findings · 38 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 319 · 36.1%GRADE not reported 18 · 2%Very low 198 · 22.4%Low 186 · 21.1%Moderate 147 · 16.6%High 15 · 1.7%

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 634 participants
Moderate

Summary of findings ‐ triple therapy: VX‐659‐tezacaftor‐ivacaftor/deutivacaftor vs control

Time to first pulmonary exacerbation · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Serum deposition Cmax · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 126 participants
Low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Adverse events · adults and children with cystic fibrosis

It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes adverse events compared with VMT (very low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
RR 0.78 [0.37, 1.64]
2 studies · 60 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 49 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT

Participant satisfaction or preference · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Treatment time nebulisation time (min) · children aged 6 ‐ 18 with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Quality of life · children aged 6 ‐ 18 with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Serum deposition Cmax · children aged 6 ‐ 18 with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Adverse events · children aged 6 ‐ 18 with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

FEV1 (% predicted): mean change from baseline · children aged 6 ‐ 18 with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Time to next exacerbation · children aged 6 ‐ 18 with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs VMT and AAD

Participant satisfaction or preference · children aged 6 ‐ 18 with cystic fibrosis

It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes participant satisfaction or preference Satisfaction scale compared with VMT and AAD (very low certainty).

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
MD 2.7 [1.35, 4.05]
1 study · 22 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Treatment time (min) · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Serum deposition Cmax · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Adverse events · adults and children with cystic fibrosis

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
Very low

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

FEV1 · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ nebulisers for delivering tobramycin: conventional systems vs AAD

Time to next exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebuliser systems for drug delivery in cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found